Penumbra IncPENEarnings & Financial Report
Penumbra, Inc. is an American medical device company headquartered in Alameda, California. The company was founded by Arani Bose and Adam Elsesser in 2004. It manufactures devices for interventional therapies to treat vascular conditions such as stroke and aneurysm.
Revenue
$339.5M
Gross Profit
$224.0M
Operating Profit
$40.8M
Net Profit
$45.3M
Gross Margin
66.0%
Operating Margin
12.0%
Net Margin
13.3%
YoY Growth
13.4%
EPS
$1.15
Financial Flow
Penumbra Inc Q2 2025 Financial Summary
Penumbra Inc reported revenue of $339.5M (up 13.4% YoY) for Q2 2025, with a net profit of $45.3M (up 175.2% YoY) (13.3% margin). Cost of goods sold was $115.4M, operating expenses totaled $183.2M.
Key Financial Metrics
| Total Revenue | $339.5M |
|---|---|
| Net Profit | $45.3M |
| Gross Margin | 66.0% |
| Operating Margin | 12.0% |
| Report Period | Q2 2025 |
Revenue Breakdown
Penumbra Inc Q2 2025 revenue of $339.5M breaks down across 2 segments, led by Thrombectomy at $230.3M (67.8% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Thrombectomy | $230.3M | 67.8% |
| Embolization And Access | $109.2M | 32.2% |
Penumbra Inc Revenue by Segment — Quarterly Trend
Penumbra Inc revenue by segment across the last 4 reported quarters, showing how each business line (such as Thrombectomy and Embolization And Access) has evolved quarter over quarter.
| Segment | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|
| Thrombectomy | $254.7M | $236.4M | $230.3M | $226.5M |
| Embolization And Access | — | $118.3M | $109.2M | $97.6M |
Penumbra Inc Annual Revenue by Year
Penumbra Inc annual revenue history includes year-by-year totals (for example, 2025 revenue was $1.4B).
| Year | Annual Revenue |
|---|---|
| 2025 | $1.4B |
| 2024 | $1.2B |
| 2023 | $1.1B |
| 2022 | $847.1M |
Penumbra Inc Quarterly Revenue & Net Profit History
Penumbra Inc results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 2025 | $385.4M | +22.1% | $47.3M | 12.3% |
| Q3 2025 | $354.7M | +17.8% | $45.9M | 12.9% |
| Q2 2025 | $339.5M | +13.4% | $45.3M | 13.3% |
| Q1 2025 | $324.1M | +16.3% | $39.2M | 12.1% |
| Q4 2024 | $315.5M | +10.8% | $33.7M | 10.7% |
| Q3 2024 | $301.0M | +11.1% | $29.5M | 9.8% |
| Q2 2024 | $299.4M | +14.5% | $-60.2M | -20.1% |
| Q1 2024 | $278.7M | +15.4% | $11.0M | 3.9% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $278.7M | $299.4M | $301.0M | $315.5M | $324.1M | $339.5M | $354.7M | $385.4M |
| YoY Growth | 15.4% | 14.5% | 11.1% | 10.8% | 16.3% | 13.4% | 17.8% | 22.1% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $1.58B | $1.53B | $1.48B | $1.53B | $1.59B | $1.67B | $1.74B | $1.83B |
| Liabilities | $376.3M | $373.3M | $374.8M | $382.3M | $380.4M | $380.9M | $385.7M | $398.9M |
| Equity | $1.20B | $1.16B | $1.10B | $1.15B | $1.21B | $1.29B | $1.36B | $1.43B |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $38.3M | $22.6M | $56.5M | $51.1M | $49.0M | $44.9M | $58.3M | $86.5M |